Connection
Udaya Kompella to Cyclooxygenase Inhibitors
This is a "connection" page, showing publications Udaya Kompella has written about Cyclooxygenase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.301 |
|
|
|
-
Cheruvu NP, Amrite AC, Kompella UB. Effect of diabetes on transscleral delivery of celecoxib. Pharm Res. 2009 Feb; 26(2):404-14.
Score: 0.310
-
Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci. 2006 Mar; 47(3):1149-60.
Score: 0.258
-
Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res. 2004 Oct; 21(10):1797-804.
Score: 0.233
-
Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J Pharmacol. 2004 Sep 13; 498(1-3):275-8.
Score: 0.233
-
Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol. 2003 Jan 05; 458(3):283-9.
Score: 0.207
-
Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol. 2005 Mar 28; 511(2-3):191-8.
Score: 0.060